Mass General Brigham Ventures
Mass General Brigham Ventures is an early-stage venture capital firm founded in 2008 to advance new life science technologies emerging from Mass General Brigham’s vast research network. Our unique model combines first access and proprietary rights to disruptive deal flow with an established track record of new venture formation, company building, and value creation. We invest in bold, transformative innovations to develop new drugs and technologies to improve outcomes for the market benefit of patients worldwide.
The Translation Innovation Fund was created in 2019 to address the funding gap between basic research or drug discovery and clinical proof-of-concept.
TIF amplifies the value of pre-commercial projects prior to their commercialization. TIF-funded projects execute on a translational plan developed alongside the PI, that is operated on their behalf by TIF staff. Our focus is on discoveries with high commercial potential from the Mass General Brigham network of hospitals.
The Innovation Discovery Grants (IDG) program aims to enhance the Mass General Brigham community's commercial outcomes and increase its innovative potential. Its design is intended to stimulate new inventive concepts, identify commercially significant scientific strength areas, and accelerate the commercialization of Mass General Brigham intellectual assets.
Please visit IDG to learn more about us.
The Summit Fund
The Mass. Eye and Ear Summit Fund was launched with the goal of raising philanthropic support from friends of Mass. Eye and Ear to help fast-track the translation of laboratory discoveries into approved medical devices and pharmaceutical treatments to improve the lives of patients. These philanthropic gifts are augmented by additional funding from Mass. Eye and Ear long-term investment pool.
The Summit Fund focuses on unmet medical needs in the fields of hearing and vision disorders.
Please visit The Summit Fund to learn more about them.
The Artificial Intelligence and Digital Innovation Fund was established in 2020 to invest in commercial stage digital health and AI based companies that address unmet needs at Mass General Brigham and are not based on technologies emerging from the health system.
A $30M fund, we work closely with the health system’s clinical, operations, research and digital leadership to identify key areas for investment focus and with Innovation’s Business Development group to identify potential co-development opportunities. We seek to co-invest with strong syndicate partners who can help these early commercial companies scale.
- For more information about AIDIF, please contact Gaye Bok, Partner